00:03 , Aug 23, 2019 |  BC Innovations  |  Distillery Therapeutics

KRAS inhibitor combinations for improved therapeutic efficacy

DISEASE CATEGORY: Cancer INDICATION: Lung cancer, pancreatic cancer UCSF’s Kevan Shokat and colleagues have identified two sets of genes for which inhibition could improve the efficacy of KRAS G12C inhibitors. Through a CRISPR-based screen in...
00:59 , Aug 22, 2019 |  BC Extra  |  Company News

Aug. 21 Company Quick Takes: GSK, FibroGen take regulatory steps forward for HIF-PH inhibitors in Asia; plus Xtandi, Biotheus/Alligator and more

GSK seeking approval of HIF-PH inhibitor in Japan  GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) said it submitted an NDA to Japan's Ministry of Health, Labour and Welfare for daprodustat to treat patients with renal anemia due to...
11:00 , Aug 21, 2019 |  BC Extra  |  Financial News

Oncorus raises $79.5M series B with eye on global development

Nearly half a dozen Korean investment groups joined Oncorus' $79.5 million series B round as part of the company's long-range plan to take its oncolytic virus technology global. Cowen Healthcare Investments and Perceptive Advisors led...
23:52 , Aug 8, 2019 |  BC Innovations  |  Tools & Techniques

Checkpoint inhibitors are bringing oncolytic viruses back into the spotlight

Early clinical readouts for next-generation oncolytic viruses are hinting at high efficacy when combined with checkpoint inhibitors, and pharmas are off to the races to find the best pairings. After more than two decades of...
19:30 , Aug 7, 2019 |  BC Extra  |  Financial News

VCs recapitalize Cleave around next-gen molecule

Seven of the 10 investors in Cleave Therapeutics' existing syndicate have agreed to recapitalize the company with a new $12 million round, with which Cleave will test a second-generation cancer compound following a toxicity snag...
11:12 , Jul 23, 2019 |  BC Extra  |  Financial News

Frequency raises $62M to fund Phase II of hearing loss therapy

Days after a deal with Astellas for FX-322, Frequency has raised a $62 million series C round led by Perceptive Advisors that will help fund a Phase IIa trial of the regenerative therapy for hearing...
07:02 , Jul 17, 2019 |  BC Extra  |  Company News

On heels of trial readout, Frequency out-licenses hearing loss therapy to Astellas

Frequency has found a partner in Astellas for its regenerative therapy to treat hearing loss in a deal that will support development of FX-322 as it moves into Phase IIa testing next quarter. Astellas Pharma...
00:02 , Jul 17, 2019 |  BC Extra  |  Company News

July 16 Company Quick Takes: Mazumdar-Shaw, Mukherjee to bring CAR Ts to India; plus Cipla, Celgene, Novartis, Seattle Genetics

Immuneel founded to bring CAR T therapies to India  Kiran Mazumdar-Shaw and Siddhartha Mukherjee founded Immuneel Therapeutics Ltd. (Bangalore, India) with the goal of providing affordable CAR T cell therapies to Indian patients. Mazumdar-Shaw is...
22:35 , Jul 11, 2019 |  BC Innovations  |  Emerging Company Profile

Twentyeight-Seven’s bet on RNA-binding proteins

Twentyeight-Seven is building a small molecule platform to target interactions between non-coding RNAs and an emerging target class in gene regulation: RNA-binding proteins. Launched last September, the company is using an $82.8 million series A...
01:58 , Jun 29, 2019 |  BioCentury  |  Finance

Biotech backs down in 2Q19

In a reversal from 1Q19, biotech stocks across all market cap tiers fell in the second quarter, leading to a total loss of $22.3 billion. However, the year-to-date change in market cap remains well in...